期刊文献+

青浦区552株结核分枝杆菌原发耐药性分析 被引量:1

Analysis of primary drug resistance of 552 strains of Mycobacterium tuberculosis in Qingpu district
在线阅读 下载PDF
导出
摘要 目的了解青浦区1999年~2008年新登记肺结核患者的原发耐药情况。方法采用绝对浓度法对新发初治肺结核患者痰标本培养菌株进行链霉素(S)、异烟肼(H)、利福平(R)和乙胺丁醇(E)4种抗结核药物的耐药性测定,统计分析原发耐药情况。结果原发总耐药率由1999年~2000年的9.2%上升至2007年~2008年的15.5%;S、H、E的耐药率由1999年的5.0%、7.1%、2.8%上升至2008年的12.1%、13.8%、3.4%;R的耐药率由1999年的5.0%下降至2007年~2008年的4.3%;原发耐多药率(MDR-TB)平均为4.5%。2药、3药的耐药率分别由1999年的2.1%、0%上升至2008年的6.0%、1.8%。1药、4药的耐药率基本在同一水平。结论青浦区肺结核患者临床分离株原发耐药性成上升趋势,耐多药菌株仍占一定比例。 Objective To illustrate the primary drug-resistance of new register of mycobacterium tuberculosis(MTB) in Qingpu 1999 - 2008. Methods Absolute concentration method was used for the detection of drug sensitivity of four kinds of anti-tuberculosis agents such as IMH, SM, KFP, EMB. The circumstance of primm'y drug resistance of MTB was analyzed. Results The rate of total primary drug resistance to SM,IMH and EMB were 5.0% ,7.1% and 2.8%, respectively in 1999 - 2000 and increase to 12. 1%, 13.8% and 3.4% in 2007 - 2008, while the rate of primary drug resistance to RIP was 5.0% in 1999- 2000 and decreased to 4.3 % in 2007- 2008, the average rate of primary MDR-TB was 4. 5%. The rale of drug resistance to two kinds of drug and three kinds of drug were 2. 1% and 0% respectively in 1999 - 2000, and increased to 6. 3 %, and 1.8% in 2007 - 2008. Another two kinds were at the same level. Conclusion The primary drug resistance of M tuberculosis in Qingpu 1999 - 2008 is in a trend of increase and multi-drug resistance is still seriously existed.
出处 《临床肺科杂志》 2010年第6期810-811,共2页 Journal of Clinical Pulmonary Medicine
关键词 分枝杆菌 结核 药物耐受性 监测 mycobacterium tuberculosis drug resistance
  • 相关文献

参考文献5

二级参考文献20

共引文献1394

同被引文献30

  • 1包洪,于庭,印璞,刘爱忠,张吉平.中国部分地区结核分支杆菌耐利福平、异烟肼和链酶素耐药基因的检测[J].中国实验诊断学,2007,11(2):232-234. 被引量:8
  • 2World Health Organization. Anti-Tuberculosis Drug Resistance inthe World. Report No. 2 Prevalence and Trends [ R ]. Geneva:WHO ,2000.
  • 3World Health Organization. Global tuberculosis control:a short up-date to the 2009 report[R]. Geneva: WHO,2009.
  • 4World Health Organization. Global tuberculosis controls urveillance,planning, financing ; WHO report 2008 [ R ] Geneva : WHO ,2008.
  • 5Wright A,Zignol M, Van-Deun A,ef al. Epidemiology of antituber-culosis drug resistance 2002-07 :an updated analysis of the GlobalProject on Anti-Tuberculosis Drug Resistance Surveillance [ J ].Lancet,2009,373(9678) :1861-1873.
  • 6中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007_2008)[M].北京:人民卫生出版社,2010:30.
  • 7Rouse DA,Morris SL. Molecular mechanisms of isoniazid resistancein Mycobacterium tuberculosis and Mycobacterium bovis[ J]. InfectImmun,1995,63(4) : 1427-1433.
  • 8Ano H, Matsumoto T, Nangi T, et al. Resistance-conferring muta-tions of Mycobacterium tuberculosis strains with low level resist-ance to isoniazid[ J] . Kekkaku,2006,81 ( 12) :709-713.
  • 9Ramaswamy S,Musser JM. Molecular genetic basis ofantimicrobialagent resistance in Mycobacterium tuberculosis: 1998 update[ J].Tuber Lung Dis,1998 ,79( 1 ) :3-29.
  • 10Lee JS,Poo H, Han DP,et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike pro-tein on Lactobacillus casei induces neutralizing antibodies in mice[J]. J Virol,2006,80(8) :40794087.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部